Clinical Experience of Life-Threatening Dabigatran-Related Bleeding at a Large, Tertiary Care, Academic Medical Center: A Case Series

Journal of Medical Toxicology

Volumn 10, Issue 2, 2014, Pages 223-228

  Ross, Britney ^a   Miller, Melissa A ^b   Ditch, Kristen ^a   Tran, Maichi ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

^b Department of Medicine   (United States)

Author keywords

Dabigatran; New oral anticoagulant; Reversal

Indexed keywords

CREATININE; DABIGATRAN; FRESH FROZEN PLASMA; HEMOGLOBIN; INFUSION FLUID; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CREATININE CLEARANCE; DEATH; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MORTALITY; PROTHROMBIN TIME; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; ANALOGS AND DERIVATIVES; CASE REPORT; CHEMICALLY INDUCED; FATALITY; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TERTIARY CARE CENTER; TREATMENT OUTCOME; UNITED STATES; UNIVERSITY HOSPITAL; VERY ELDERLY;

ACADEMIC MEDICAL CENTERS; AGED; AGED, 80 AND OVER; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; COMBINED MODALITY THERAPY; FATAL OUTCOME; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MASSACHUSETTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84902379444     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-013-0364-1     Document Type: Article

References (21)

1. Boriani G, Diemberger I (2012) Editorial. Globalization of the epidemiologic, clinical, and financial burden of atrial fibrillation. Chest 142(6): 1368-1370.
2. You JJ, Singer DE, Howard PA et al (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl): e531S-e575S.
3. (2012) Product information: PRADAXA® oral capsules, dabigatran etexilate mesylate oral capsules. Boehringer Ingelheim Pharmaceuticals, Inc. (per FDA), Ridgefield.
4. U. S. Food and Drug Administration (2012) FDA drug safety communication: update on the risk for serious bleeding events with the anticoagulant Pradaxa. U. S. Food and Drug Administration (FDA), Silver Spring. http://www. fda. gov/drugs/drugsafety/ucm326580. htm Accessed 4 Nov 2012.
5. Wood S (2011) Dabigatran: 260 fatal bleeds since approval worldwide. Theheart. org. [Clinical conditions > Arrhythmia/EP > Arrhythmia/EP]. http://www. theheart. org/article/1314809. do. Accessed 1 Mar 2013.
6. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12): 1139-1151.
7. Schattner A, Kozak N, Friedman J (2013) Case report: fatality in a patient treated with dabigatran. Am J Emerg Med 31(2): 443. e1-443. e2.
8. Warkentin TE, Margetts P, Connolly SJ et al (2012) Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 119(9): 2172-2174.
9. Cano EL, Miyares MA (2012) Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. J Geriatr Pharmacother 10: 160-163.
10. Dy EA, Shiltz DL (2012) Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother 46(7-8): e18.
11. Legrand M, Mateo J, Aribaud A et al (2011) The use of dabigatran in elderly patients. Arch Intern Med 171(14): 1285-1288.
12. Garber ST, Sivakumar W, Schmidt RH (2012) Neurosurgical complications of direct thrombin inhibitors-catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg 116(5): 1093-1096.
13. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14): 1573-1579.
14. Zhou W, Schwarting S, Illanes S et al (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 42: 3594-3599.
15. Ageno W, Gallus AS, Wittkowsky A et al (2012) Antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl): e44S-e88S.
16. Dager WE, Gosselin RC, Roberts J (2013) Reversing dabigatran in a life-threatening bleed occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 41: 1-5.
17. Chen BC, Viny AD, Garlich FM et al (2012) Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila) 50: 854-857.
18. van Ryn J, Stangier J, Haetter S et al (2010) Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103: 1116-1127.
19. Escolar G, Arellano E, Carne X, et al. (2012) Evaluation of the potential action of coagulation factors concentrates in the reversal of the antithrombotic action of new oral anticoagulants: studies ex vivo in blood samples from healthy volunteers. Clinicaltrials. gov. www. clinicaltrials. gov/ct2/show/NCT01478282. Accessed 1 Mar 2013.
20. Pernod G (2011) Reversion of the anticoagulant effect of the new antithrombotic agents anti-Xa and anti-IIa by specific and non-specific haemostatic drugs: an ex-vivo study in healthy volunteers. Clinicaltrials. gov. www. clinicaltrials. gov/ct2/show/NCT01210755. Accessed 1 Mar 2013.
21. van Ryn J, Litzenburger T, Waterman A et al (2011) Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 57(14): E1130 (abstr).